RxDoctor Payments Data

Adela Mattiazzi, MD

Nephrology · Miami, FLNPI 1922200260

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Novo Nordisk at 31.1% of the total. 2025 is the largest year on record at $333, 7.3 times the $46 reported in 2019. That places this record below the midpoint for nephrology clinicians in FL, where the typical reported total is $1,407.

$738in general payments, 2019–2025

Across 9 payments — averaging $81.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$230
  • Veloxis Pharmaceuticals, Inc.$176
  • Calliditas Therapeutics US Inc.$154
  • Kaneka Medical America LLC$103
  • Novartis$75
$105,441in research payments, 2019–2025

Across 12 payments — averaging $8786.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$54K
  • Shire North American Group Inc$40K
  • Takeda Pharmaceuticals U.S.A., Inc.$12K

What the payments were for

  • Food & beverage$738100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$738 in reported general payments places this provider in the 35th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida →

Medicare billing

Part B allowed, 2024
$90,346
Medicare patients
239
Services billed
872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-50121$2,053,861
OctagamImmun Globg(Igg)/Malt/Iga Ov5087$1,709,611
GammakedImmune Globul G/Gly/Iga Avg 4646$1,045,959
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5035$512,634
ProcritEpoetin Alfa30$101,252
VeltassaPatiromer Calcium Sorbitex44$46,644
Cinacalcet Hcl167$37,967
LokelmaSodium Zirconium Cyclosilicate40$31,903
FarxigaDapagliflozin Propanediol50$31,890
ZarxioFilgrastim-Sndz25$23,185
Atovaquone32$20,021
EliquisApixaban28$15,736
Valganciclovir Hcl56$14,837
RetacritEpoetin Alfa-Epbx14$12,788
Mycophenolic AcidMycophenolate Sodium25$10,354

Paid to pharmacies, not to this prescriber.

Other nephrology in Miami

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →